Clinical Trial Update: SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SBRT followed by chemoimmunotherapy with toripalimab, docetaxel, and cisplatin to preserve the larynx in patients with locally region…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Status: RECRUITING